The EW stock price forecast this month considers qualitative factors like FDA approvals likely to come in H2, which could act as catalysts for upward price moves above $100. 22% = US$1.4b ÷ US$6.4b (Based on the trailing twelve months to June 2023). We have seen 574 institutional investors add shares of $EW stock to their portfolio, and 640 decrease their positions in their most recent quarter. Traders eyeing EW note that options market activity has skewed toward calls, signaling growing bullish speculation. This sentiment reinforces the positive stock price forecast for the next earnings cycle.